Publication date: Available online 13 November 2026 Source: Molecular Therapy Advances Author(s): Sarah Saietz, Laura Baqué-Vidal, Heather Main, Hazel Reilly, Mona Hedenskog, Nefeli-Eirini Beri, Hugo Metzger, Paschalis Efstathopoulos, Frederik Bär, Eda Erbil, Andreas Wrona, Christoffer von Halling Laier, Daniel R. Muth, Flavia Plastino, Yesenia Ortega Melin, Ásbjörg Geirsdóttir, Sandeep Kumar, Sara Mangosing, Svetlana Nikoulina, Linda Manza
From GMP manufacture of CellThRPE1 to regulatory authorisation of a First-in-Human Phase I clinical trial in geographic atrophy. // Molecular Therapy Advances. – URL: https://www.sciencedirect.com/science/article/pii/S3117387X26002405?dgcid=rss_sd_all
From GMP manufacture of CellThRPE1 to regulatory authorisation of a First-in-Human Phase I clinical trial in geographic atrophy. Molecular Therapy Advances. https://www.sciencedirect.com/science/article/pii/S3117387X26002405?dgcid=rss_sd_all
“From GMP manufacture of CellThRPE1 to regulatory authorisation of a First-in-Human Phase I clinical trial in geographic atrophy.” Molecular Therapy Advances.
@article{article59083,
title = {From GMP manufacture of CellThRPE1 to regulatory authorisation of a First-in-Human Phase I clinical trial in geographic atrophy},
journal = {Molecular Therapy Advances},
url = {https://www.sciencedirect.com/science/article/pii/S3117387X26002405?dgcid=rss_sd_all}
}